PRÆMED.BIO for better cancer diagnostics
Leading companies and research institutes in oncology, diagnostics, automation and micro-nano-bio research, including MEDIPAN, Attomol, PolyAn, Cybertron, DKFZ, DKTK, TU Dresden and BTU Cottbus-Senftenberg, have joined forces to investigate next generation technologies with the goal of enabling a new integrated platform for precision medicine in oncology. The PRÆMED.BIO project receives total funding of €10 million from the German Federal Ministry of Education and Research (BMBF).
Leading companies and research institutes in oncology, diagnostics, automation and micro-nano-bio research, including MEDIPAN, Attomol, PolyAn, Cybertron, DKFZ, DKTK, TU Dresden and BTU Cottbus-Senftenberg, have joined forces to investigate next generation technologies with the goal of enabling a new integrated platform for diagnostics for precision medicine in oncology.
Modern cancer therapy is caught between technological and scientific developments, demographic change, optimal patient care and affordable services. This challenging situation for patients, physicians and healthcare payers can be addressed by precision medicine that is based on personalized diagnostics. This allows patients to be stratified prior to therapy to receive an optimal treatment.
To realize this vision, a modular, multiparametric and fully automated analysis system (PRÆMED.BIO-Scan) based on digital fluorescence shall be developed. Both hardware, software and novel consumables will be fully integrated within the development. The platform will also take advantage and enable the development of new biomarkers for the characterization of head & neck as well as rectal carcinomas. The project includes the validation of various biomarkers for these oncological indications and the clinical testing of the entire system.
The PRÆMED.BIO alliance integrates the expertise of leading technology providers from entire value chain for medical diagnostics, i.e. instrument design, development of new diagnostic parameters, validation / certification, production and distribution of diagnostic multiplex tests, manufacturing of consumables, and routine clinical diagnostics. The know-how of the partners leads to the core competence "Digital Fluorescence", which includes the development of devices and testing. This expertise is complemented by system automation and clinical expertise in tumor diagnostics.
PRÆMED.BIO has established an advisory board with stakeholders from various disciplines in order to capture their insights for the development of a diagnostic platform that will suit the societal needs. The outcomes of the project will be shared with the general and scientific public by publications and conference contributions.
For further information about this project please contact:
- Dr. Uwe Schedler, Geschäftsführer PolyAn GmbH
- Email: email@example.com
PolyAn is a nanotechnology company specialized in the modification of surfaces using Molecular Surface Engineering (MSE). Since 1996 PolyAn develops and manufactures consumables for applications that require high signal-to-noise ratios. Our products include supports for microarrays, fluorescence encoded microparticles and calibration tools for fluorescence imaging systems.